As curcumin diminished PD-L1 expression in cancer cells, antitumor immunity was improved, and cancer cells were sensitized to anti-CTLA-4 therapy in multiple animal models (including breast cancer), bringing to light the role of curcumin as an adjuvant to immune checkpoint therapies (ICT) [230]. This evidence concerns the gene CTLA4 and cancer.